What's Happening?
Researchers at Yale University have discovered that levocarnitine, a low-cost drug already on the market, may help alleviate symptoms of autism spectrum disorder (ASD) in certain individuals. The study
involved testing 774 FDA-approved drugs on zebrafish genetically modified to exhibit autism-like traits. Levocarnitine was found to restore normal function in zebrafish with mutations in the SCN2A and DYRK1A genes, which are linked to brain development and autism-related traits. However, these mutations are rare, suggesting the drug would only benefit a small subset of people with ASD. The research highlights the importance of studying known autism risk genes, of which more than 800 have been identified, to find potential treatments.
Why It's Important?
The findings are significant as they offer a potential new treatment avenue for ASD, a condition with rising diagnoses in the U.S. and limited treatment options. The study underscores the potential of repurposing existing drugs to address specific genetic mutations associated with autism. This approach could lead to more personalized treatments, benefiting those with rare genetic profiles. The research also emphasizes the need for further exploration of genetic factors in autism, which could pave the way for more targeted therapies and improve the quality of life for affected individuals.
What's Next?
While the study's results are promising, the researchers caution against using levocarnitine as a treatment for ASD without further testing in humans. The next steps involve clinical trials to assess the drug's efficacy and safety in humans with the specific genetic mutations identified. Additionally, the open-source database of drugs compiled by the researchers could facilitate future discoveries and the development of new treatments for autism and other neurodevelopmental disorders.
